Startseite>>Signaling Pathways>> Others>>CNT2 inhibitor-1

CNT2 inhibitor-1

Katalog-Nr.GC30562

CNT2-Inhibitor-1 ist ein potenter konzentrativer Nukleosid-Transporter-2-Inhibitor (CNT2) mit einem IC50-Wert von 640 nM fÜr hCNT2.

Products are for research use only. Not for human use. We do not sell to patients.

CNT2 inhibitor-1 Chemische Struktur

Cas No.: 880155-70-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
556,00 $
Auf Lager
5mg
506,00 $
Auf Lager
10mg
782,00 $
Auf Lager
25mg
1.609,00 $
Auf Lager
50mg
2.528,00 $
Auf Lager
100mg
3.631,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2.

CNT2 inhibitor-1 (compound 48) exhibits 81-fold more potent inhibitory activity than the parent compound 12. In addition, CNT2 inhibitor-1 exhibits inhibitory activity 1500-fold more potent than that of 2'-deoxy-5-fluorouridine, phlorizin, and 7,8,3'-trihydroxyflavone, which are well-known hCNT2 inhibitors[1]. CNT2 inhibitor-1 (compound 1) is a potent inhibitor with poor solubility[2].

[1]. Tatani K, et al. Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors. ACS Med Chem Lett. 2015 Jan 28;6(3):244-8.

Bewertungen

Review for CNT2 inhibitor-1

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CNT2 inhibitor-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.